Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 3/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | LSS | P48449 | 2/20 | 0.30 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18295981 | 0.95 | SSTR4 (0.31) | ATMSSTR4 | |
| SCHEMBL20163529 | 0.87 | LSS (0.34) | ATMLSS | |
| SCHEMBL20163533 | 0.87 | LSS (0.34) | ATMLSS | |
| SCHEMBL20176320 | 0.86 | SSTR4 (0.30) | SSTR4 | |
| SCHEMBL20173486 | 0.84 | SSTR4 (0.31) | SSTR4 | |
| SCHEMBL20163447 | 0.84 | LSS (0.36) | LSSSSTR4 | |
| SCHEMBL20173473 | 0.83 | GLA (0.34) | — | |
| SCHEMBL20173488 | 0.83 | — | — | |
| SCHEMBL20173480 | 0.83 | CHEK2 (0.32) | SSTR4 | |
| SCHEMBL20173485 | 0.82 | SSTR4 (0.31) | SSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200255415-A1 | TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF BREAST CANCER | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2020-08-13 | — | — | US | disclosed |
| US-20180141913-A1 | TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141913-A1 | TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE | BRCA1, ESR2, ESR1 | ATM 1164/4885CA14 2780/4885LSS 1479/4885 |
| US-20200255415-A1 | TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF BREAST CANCER | BRCA1, ESR2, ESR1 | ATM 721/4885CA14 2942/4885LSS 1365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.